Hong Ruoxi, Ma Fei, Shi Xiuqing, Li Qing, Zhang Pin, Yuan Peng, Wang Jiayu, Fan Ying, Cai Ruigang, Li Qiao, Xu Binghe
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Email:
Zhonghua Zhong Liu Za Zhi. 2014 Oct;36(10):788-92.
To compare the effect of first-line treatment with platinum-based chemotherapy and non-platinum-based chemotherapy in patients with lung metastases from triple negative breast cancer (TNBC).
Sixty-five eligible patients were divided into platinum-treated group and non-platinum-treated group according to the first-line therapy. Factors predicting the chemotherapeutic efficacy included overall survival (OS), progression-free survival (PFS) and objective response (OR).
In the platinum-treated group of 32 patients, 2 cases (6.3%) achieved CR, 16 cases (50.0%) achieved PR, 11 (34.4%) cases achieved SD, and 3 patients (9.4%) achieved PD. In the non-platinum-treated group of 33 patients, 2 cases (6.1%) achieved CR, 6 cases (18.2%) achieved PR, 16 cases (48.5%) achieved SD, and 9 cases (27.3%) achieved PD. Median PFS was significantly longer in the platinum-treated group than in the non-platinum-treated group (10 months vs. 6.0 months, P = 0.012), and OS was also improved (32 months vs. 22 months, P = 0.006). Multivariate analysis of several factors including local-regional lymph node involvement, lung metastasis-related symptoms, first-line platinum-based chemotherapy, disease-free interval, size and number of lung lesions, showed that first-line platinum-based chemotherapy was an independent prognostic factor for TNBC patients with lung metastases.
Compared with non-platinum-based chemotherapy, the first-line platinum-based chemotherapy can improve PFS and OS in TNBC patients with metastases confined to the lungs.
比较一线铂类化疗与非铂类化疗对三阴性乳腺癌（TNBC）肺转移患者的治疗效果。
65例符合条件的患者根据一线治疗方案分为铂类治疗组和非铂类治疗组。预测化疗疗效的因素包括总生存期（OS）、无进展生存期（PFS）和客观缓解率（OR）。
在32例铂类治疗组患者中，2例（6.3%）达到完全缓解（CR），16例（50.0%）达到部分缓解（PR），11例（34.4%）达到疾病稳定（SD），3例（9.4%）疾病进展（PD）。在33例非铂类治疗组患者中，2例（6.1%）达到CR，6例（18.2%）达到PR，16例（48.5%）达到SD，9例（27.3%）达到PD。铂类治疗组的中位PFS显著长于非铂类治疗组（10个月对6.0个月，P = 0.012），OS也有所改善（32个月对22个月，P = 0.006）。对包括局部区域淋巴结受累、肺转移相关症状、一线铂类化疗、无病间期、肺病灶大小和数量等多个因素进行多变量分析，结果显示一线铂类化疗是TNBC肺转移患者的独立预后因素。
与非铂类化疗相比，一线铂类化疗可改善局限于肺部转移的TNBC患者的PFS和OS。
